Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.

CONCLUSION: The recommended S-1 dose was 40 mg/m2 , twice daily on Monday, Wednesday, Friday, and Sunday, with 25 mg oral leucovorin twice daily and 5 mg/kg bevacizumab every 2 weeks. Compared with the daily administration, alternate-day administration may reduce mucositis with promising antitumor activity in refractory mCRC.
PMID: 32490554 [PubMed - as supplied by publisher]

Source: The Oncologist - June 2, 2020 Category: Cancer & Oncology Authors: Masuishi T, Taniguchi H, Komori A, Mitani S, Narita Y, Kadowaki S, Ura T, Ando M, Muro K Tags: Oncologist Source Type: research